



000000

تم رفع هذه الرسالة بواسطة / سنوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات:





FRAILITY IN HEMODIALYSIS PATEINT

Thesis

Submitted for Partial Fulfillment of
Master Degree in **Internal Medicine**

By

Ahmed Amgad Hosny Elsayed Atta
M.B.B.Ch, Faculty of Medicine, Ain Shams University

Under Supervision of

Prof. Khaled Hussein Abou Seif

Professor of Internal Medicine and Nephrology
Faculty of Medicine– Ain Shams University

Prof. Magdy Mohamed Saied El Sharkawy

Professor of Internal Medicine and Nephrology
Faculty of Medicine– Ain Shams University

Dr. Mohamed Saeed Hassan

Lecturer of Internal Medicine and Nephrology
FACULTY OF MEDICINE– AIN SHAMS UNIVERSITY

Faculty of Medicine
Ain Shams University

2022

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَّحَانَكَ لَا يَعْلمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to
Allah the Most Beneficent and Merciful.*

**MY PROFOUND THANKS AND DEEP APPRECIATIONS TO
Prof. Khaled Hussein Abou Seif, PROFESSOR OF INTERNAL
MEDICINE AND NEPHROLOGY, FACULTY OF MEDICINE, AIN
SHAMS UNIVERSITY FOR HIS GREAT SUPPORT AND ADVICE,
HIS VALUABLE REMARKS THAT GAVE ME THE CONFIDENCE
AND ENCOURAGEMENT TO FULFILL THIS WORK.**

**MY PROFOUND THANKS AND DEEP APPRECIATIONS TO
Prof. Magdy Mohamed Saied El Sharkawy, PROFESSOR
OF INTERNAL MEDICINE AND NEPHROLOGY, FACULTY OF
MEDICINE, AIN SHAMS UNIVERSITY FOR HIS GREAT SUPPORT
AND VALUABLE REMARKS, METICULOUS SUPERVISION AND
CONTINUOUS SUPPORT.**

**I AM ALSO THANKFUL TO Dr. Dr. Mohamed Saied,
LECTURER OF INTERNAL MEDICINE AND NEPHROLOGY,
FACULTY OF MEDICINE, AIN SHAMS UNIVERSITY FOR HIS
METICULOUS SUPERVISION, VALUABLE ADVICE AND
CONSTRUCTIVE CRITICISM.**

**I WOULD LIKE TO EXPRESS MY HEARTY THANKS TO ALL
MY FAMILY FOR THEIR SUPPORT TILL THIS WORK WAS
COMPLETED.**

**LAST BUT NOT LEAST MY SINCERE THANKS AND
APPRECIATION TO ALL PATIENTS PARTICIPATED IN THIS
STUDY.**

Ahmed Amgad

List of Contents

Title	Page No.
LIST OF ABBREVIATIONS.....	I
LIST OF TABLES	II
LIST OF FIGURES	IV
INTRODUCTION	1
AIM OF THE WORK.....	3
REVIEW OF LITERATURE	
▪ HEMODIALYSIS.....	4
▪ FRAILITY.....	18
▪ FRAILITY IN HEMODIALYSIS PATIENTS	43
PATIENTS AND METHODS.....	54
RESULTS	61
DISCUSSION.....	94
CONCLUSIONS AND RECOMMENDATIONS.....	107
SUMMARY	108
REFERENCES	111
ARABIC SUMMARY	

List of Abbreviations

Abb.	Full term
AVF.....	ARTERIOVENOUS FISTULA
AVG.....	ARTERIOVENOUS GRAFT
AWGS.....	ASIAN WORKING GROUP FOR SARCOPENIA
BMI.....	BODY MASS INDEX
BUN.....	BLOOD UREA NITROGEN
CGA.....	COMPREHENSIVE GERIATRIC ASSESSMENT
CKD.....	CHRONIC KIDNEY DISEASE
EFL.....	ELECTRONIC FRAILTY INDEX
EFS.....	EDMONTON FRAIL SCALE
EGFR.....	ESTIMATED GLOMERULAR FILTRATION RATE
ESRD.....	END-STAGE RENAL DISEASE
HBV.....	HEPATITIS B VIRUS
HCV.....	HEPATITIS C VIRUS
HD.....	HEMODIALYSIS
IPAQ.....	INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE
KFACS.....	KOREAN FRAILTY AND AGING COHORT STUDY
KRT.....	KIDNEY REPLACEMENT THERAPY
LMICS.....	LOW- AND MIDDLE-INCOME COUNTRIES
PMP.....	PERMILLION POPULATION
PTH.....	PARATHYROID HORMONE
QoL.....	QUALITY OF LIFE
RKF.....	RESIDUAL KIDNEY FUNCTION

List of Tables

Table No.	Title	Page No.
TABLE 1:	ENGLISH VERSION OF THE FRAILTY PHENOTYPE QUESTIONNAIRE.....	27
TABLE 2:	JAPANESE VERSION OF THE CARDIOVASCULAR HEALTH STUDY CRITERIA.....	28
TABLE 3:	FIVE ITEMS OF FRIED'S FRAILTY PHENOTYPE AND ITS CUTOFF REFERENCE.....	29
TABLE 4:	EDMONTON FRAIL SCALE.....	31
TABLE 5:	COMPARISON OF FRAILTY PHENOTYPE AND FRAILTY INDEX.....	32
TABLE 6:	THE TILBURG FRAILTY INDICATOR.....	33
TABLE 7:	THE KIHON CHECKLIST	34
TABLE 8:	THE SIMPLE "FRAIL" QUESTIONNAIRE SCREENING TOOL.....	36
TABLE 9:	THE FIVE-ITEM FRAILTY SCREENING INDEX.....	36
TABLE 10:	THE CLINICAL FRAILTY SCALE (CFS).....	37
TABLE 11:	LIST OF 36 DEFICITS CONTAINED IN THE ELECTRONIC FRAILTY INDEX IN UK NATIONAL HEALTH SERVICE.....	39
TABLE 12:	THE EDMONTON FRAIL SCALE.....	58
TABLE 13:	DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR DEMOGRAPHIC DATA REGARDING GENDER AND AGE (N=300).....	61
TABLE 14:	DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR LABORATORY DATA REGARDING ALT, AST, ALK, ALB., NA, K+, CA, PO₄, IRON, TIBC, CR, BUN, HGB AND PTH (N=300).....	63
TABLE 15:	DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR HEPATITIS REGARDING HBV, HCV AND HIV (N=300).....	65

List of Tables cont...

Table No.	Title	Page No.
TABLE 16:	DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR EDMONTON FRAIL SCALE (N=300).....	67
TABLE 17:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO DEMOGRAPHIC DATA REGARDING AGE AND SEX.....	69
TABLE 18:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO LABORATORY DATA REGARDING ALT, AST, ALK, ALB, NA, K+, CA, PO4, IRON, TIBC, CR, BUN, HGB AND PTH.....	72
TABLE 19:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO HEPATITIS C VIRUS (HCV).....	76
TABLE 20:	CORRELATION BETWEEN EDMONTON FRAIL SCALE ACCORDING TO HEPATITIS C VIRUS (HCV).....	77

List of Figures

Fig. No.	Title	Page No.
FIGURE 1:	CURRENT AND PROJECTED PREVALENCE OF KIDNEY FAILURE REQUIRING KIDNEY REPLACEMENT THERAPY	7
FIGURE 2:	PRINCIPLE OF HEMODIALYSIS.....	8
FIGURE 3:	HEMODIALYSIS CATHETER ACCESS.....	12
FIGURE 4:	ARTERIOVENOUS FISTULA.....	13
FIGURE 5:	ARTERIOVENOUS GRAFT	14
FIGURE 6:	RESPONSE TO A STRESSOR EVENT IN A NONFRAIL VS FRAIL OLDER PERSON	18
FIGURE 7:	PATHOGENESIS OF THE FRAILTY	23
FIGURE 8:	CONCEPTUAL MODELS OF FRAILTY.....	25
FIGURE 9:	KIHON CHECKLIST OF 25 ITEMS AND SEVEN CATEGORIES FOR SCREENING "SPECIFIED ELDERLY" INDIVIDUALS FOR FRAILTY.....	38
FIGURE 10:	ADVERSE HEALTH OUTCOMES OF FRAILTY.....	42
FIGURE 11:	POTENTIAL CONTRIBUTORS TO FRAILTY IN CKD PATIENTS.....	45
FIGURE 12:	POTENTIAL COMPLICATIONS OF FRAILTY IN CKD PATIENTS	48
FIGURE 13:	PIE CHART DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR DEMOGRAPHIC DATA REGARDING AGE GROUP.....	62
FIGURE 14:	PIE CHART DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR DEMOGRAPHIC DATA REGARDING SEX.	62
FIGURE 15:	PIE CHART DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR HCV.....	66
FIGURE 16:	PIE CHART DISTRIBUTION OF HEMODIALYSIS PATIENTS CASES ACCORDING TO THEIR EDMONTON FRAIL SCALE.....	68

List of Figures cont...

Fig. No.	Title	Page No.
----------	-------	----------

FIGURE 17:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO AGE GROUP.....	70
FIGURE 18:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO SEX.....	71
FIGURE 19:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO LABORATORY DATA REGARDING ALB, K+, CA, Po4 AND HGB.	75
FIGURE 20:	BOX PLOT BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO LABORATORY DATA REGARDING IRON.	75
FIGURE 21:	ASSOCIATION BETWEEN SEVERITY OF EDMONTON FRAIL SCALE ACCORDING TO HEPATITIS C VIRUS (HCV).....	76
FIGURE 22:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO AGE (YEARS).....	78
FIGURE 23:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO ALB.....	78
FIGURE 24:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO K+.....	79
FIGURE 25:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO CA.....	79
FIGURE 26:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO Po4.....	80
FIGURE 27:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO IRON.....	80
FIGURE 28:	SCATTER PLOT BETWEEN EDMONTON FRAIL SCALE ACCORDING TO HGB.....	81

INTRODUCTION

Frailty has been defined as a state of increased vulnerability to stressors as a consequence of degeneration in multiple systems. There remain two schools of thought with regard to frailty: one which sees frailty as a physical phenotype characterized by sarcopenia and another that views frailty as an accumulation of deficits across a variety of domains (*Worthen & Tennankore, 2019*).

Regardless of which definition of frailty is used, it has been shown in the general population to be predictive of adverse outcomes, including falls, hospitalization, decreased quality of life, and mortality (*Vermeiren et al., 2016*).

Frailty is highly prevalent in patients at all stages of kidney disease, with as many as two-thirds of patients with end-stage renal disease (ESRD) being identified as frail (*Kojima, 2017*). As in the general population, patients with kidney disease who are frail have been shown to be at increased risk of negative outcomes (*Chowdhury et al., 2017*).

Hemodialysis (HD) is a life-sustaining procedure for patients with end-stage kidney disease (*El Sharkawy et al., 2020*). There are solid data suggesting that frailty in patients on hemodialysis is related to the higher risk of hospitalization (*Bao et al., 2012*), falls (*McAdams-DeMarco et al., 2013*), bone loss (*Yoneki et al., 2019*) and mortality (*Bao et al., 2012*;

McAdams-DeMarco et al., 2013). With the population aging, the identification of frailty in hemodialysis is an essential and necessary emerging concept for guiding patients towards personalized treatment and maximizing their likelihood of better outcome (*Bancu et al., 2017*). In dialysis decision-making discussions, identification of frailty can help providers address prognostic concerns on conservative management (*Zhao et al., 2020*).

Questions remain around the utility of frailty screening – how exactly does frailty affect patients on hemodialysis? If a patient is identified as frail, are there interventions that can modify this? How can knowing a patient is frail inform decisions around their management? Are there effective and easily implementable screening tools available?

AIM OF THE WORK

The aim of this study was to assess the prevalence of frailty among dialysis population.

HEMODIALYSIS

Kidney failure is defined by a glomerular filtration rate $<15 \text{ ml/min/1.73 m}^2$ (KDIGO, 2013) and may be treated using KRT (which refers to either dialysis more than 3 months or transplantation) or with supportive care (*Hole et al., 2020*).

Hemodialysis is a process of purifying the blood of a person whose kidneys are not working normally. This type of dialysis achieves the extracorporeal removal of waste products such as creatinine and urea and free water from the blood when the kidneys are in a state of kidney failure. Hemodialysis is one of three renal replacement therapies (the other two being kidney transplant and peritoneal dialysis) (*Foster et al., 2018*).

Epidemiology of dialysis

The global prevalence of kidney failure is uncertain, but was estimated to be 0.07%, or approximately 5.3 million people in 2017 (*Bikbov et al., 2020*), with other estimates ranging as high as 9.7 million. Worldwide, millions of people die of kidney failure each year owing to a lack of access to kidney replacement therapy (KRT), often without supportive care. Haemodialysis is costly, and current recommendations therefore suggest that haemodialysis should be the lowest priority for low- and middle-income countries (LMICs) seeking to establish kidney care programmes (*Himmelfarb et al., 2020*).

Worldwide, approximately 89% of patients on dialysis receive haemodialysis; the majority (>90%) of patients on haemodialysis live in HICs or the so-called upper middle-income countries such as Brazil and South Africa (*Pecoits-Filho et al., 2020*).

The apparent prevalence of long-term dialysis varies widely by region but correlates strongly with national income. This variation in prevalence in part reflects true differences in dialysis use but also reflects the fact that wealthier countries are more likely than lower income countries to have comprehensive dialysis registries (*Bello et al., 2019*).

Of note, the prevalence of haemodialysis is increasing more rapidly in Latin America (at a rate of ~4% per year) than in Europe or the USA (both ~2% per year), although considerable variation between territories exists in all three of these regions, which again correlates primarily (but not exclusively) with wealth (*Luxardo et al., 2018*). The prevalence of haemodialysis varies widely across South Asia, with relatively high prevalence (and rapid growth) in India and lower prevalence in Afghanistan and Bangladesh (*Jha et al., 2019*).

A 2017 report suggests that haemodialysis services were available in at least 34 African countries as of 2017, although haemodialysis was not affordable or accessible to the large majority of resident candidates (*Bello et al., 2017*).